FuturAqua to invest HUF 400 mln in cancer research
pixabay
FuturAqua, a company listed on the Budapest Stock Exchange, will provide HUF 400 million for the clinical research and development of a Hungarian cancer drug as part of its cooperation with HYD Pharma, the latter company told Hungarian news agency MTI.
FuturAqua wants to finance its contribution partly from R&D funding and partly by raising funds on the capital market. Shareholders at FuturAquaĘĽs general meeting on Tuesday unanimously approved the cooperation.
Clinical tests on patients with chronic lymphoid leukemia (CLL) are expected to start in the first quarter of 2017, with the first official results due at the end of 2018, HYD Pharma said.
HYD Pharma conducts research and development of deuterium-depleted products.
ADVERTISEMENT
Hungary Inflation Rate at 21.5% in May
Parl't Approves Amendments to Legislation on Judiciary
Industrial Production Declines in April
Landmark Budapest Dept Store to Reopen After HUF 8 bln Renov...
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
